CSL profit jumps on robust sales

CSL, the world’s No.2 blood products maker, has reported a 19 per cent rise in full-year net profit to $US1.22 billion ($1.34 billion), as robust sales of its core products offset a strong Australian dollar.
CSL, which books 90 per cent of its revenues outside Australia, said it expected profit growth this year of around 10 per cent at constant currency rates.  Sydney Morning Herald – Read more…